Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15037944 | 0.82 | DPP4 (0.60) | DPP4SLC6A2SLC6A4CHRM2HRH3 | |
| SCHEMBL19820168 | 0.81 | DPP4 (0.55) | DPP4SLC6A2SLC6A4CHRM2HRH3 | |
| SCHEMBL12041166 | 0.79 | DPP4 (0.54) | DPP4SLC6A2SLC6A4CHRM2HRH3 | |
| SCHEMBL12041041 | 0.79 | DPP4 (0.54) | DPP4SLC6A2SLC6A4CHRM2HRH3 | |
| SCHEMBL2095327 | 0.79 | SLC6A2 (0.47) | DPP4SLC6A2SLC6A4CHRM2HRH3 | |
| SCHEMBL3389633 | 0.79 | CYP2D6 (0.56) | DPP4SLC6A2SLC6A4CHRM2HRH3 | |
| SCHEMBL3536125 | 0.79 | NOTUM (0.47) | MAPTDPP4HRH3L3MBTL1MBTD1 | |
| SCHEMBL6794719 | 0.75 | FFAR4 (0.51) | MAPTCHRM2KDM4EALDH1A1DRD2 | |
| SCHEMBL4705716 | 0.75 | MBTD1 (0.49) | SLC6A2SLC6A4CHRM2HRH3L3MBTL1 | |
| SCHEMBL4703341 | 0.75 | CYP2D6 (0.50) | DPP4SLC6A2SLC6A4CHRM2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11241436-B2 | Autophagy inducers for treatment of CNS conditions | NORTHWESTERN UNIVERSITY (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210186972-A1 | FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-06-24 | — | — | US | disclosed |
| US-10301314-B2 | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-05-28 | — | — | US | disclosed |
| US-9877966-B1 | Combination therapy for the inhibition of metastasis and tumorigenesis | OLIVA EUGENE J (US) | 2018-01-30 | — | — | US | disclosed |
| US-9877966-B1 | Combination therapy for the inhibition of metastasis and tumorigenesis | OLIVA EUGENE J (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170260192-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260192-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-14 | — | — | US | disclosed |
| US-9663521-B2 | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663521-B2 | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-05-30 | — | — | US | disclosed |
| US-20140323438-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | NORTHWESTERN UNIVERSITY | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323438-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | PGF, BRCA1, RB1 | MAPT 4130/4885DPP4 2831/4885SLC6A2 1640/4885 |
| US-20170260192-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | PGF, BRCA1, RB1 | MAPT 4130/4885DPP4 2831/4885SLC6A2 1640/4885 |
| US-20210186972-A1 | FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | FOXK1, FOXO1, FOXO3 | MAPT 4608/4885DPP4 4010/4885SLC6A2 2386/4885 |
| US-10301314-B2 | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis | PGF, BRCA1, RB1 | MAPT 4130/4885DPP4 2831/4885SLC6A2 1640/4885 |
| US-11241436-B2 | Autophagy inducers for treatment of CNS conditions | SQSTM1, ATG7, BECN1 | MAPT 335/4885DPP4 4434/4885SLC6A2 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.